Algernon Health Closes Second Tranche of Private Placement Financing

Canada‑based healthcare company Algernon Health Inc. (CSE: AGN; Frankfurt: AGW0; OTCQB: AGNPF) has officially closed the second tranche of its non‑brokered private placement (the “Offering”), originally announced on November 6, 2025 — following a first tranche closing on November 14. Under the terms of the second tranche, Algernon sold 3,000,000 units at CAD $0.07 per unit, raising CAD $210,000 in gross proceeds. No cash finder’s fees were paid in connection with the second tranche. Proceeds from the Offering are earmarked to advance Algernon’s Alzheimer’s Disease (AD) program — including funding for the opening of its first U.S.–based AD clinic — along with covering general and administrative expenses and other working capital needs. Shares issued (and issuable) under this financing, including those from the first tranche, will be subject to a statutory hold period of four months plus one day under applicable Canadian securities law. The securities have not been — and will not be — registered under the U.S. Securities Act of 1933 (or any U.S. state securities laws), and therefore cannot be offered or sold within the United States or to U.S. persons, absent proper registration or exemption under applicable U.S. laws. #AlgernonHealth #PrivatePlacement #AlzheimersResearch #HealthcareFunding #SlimScan #GrowthStocks #CANSLIM